Overview

Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
To determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.
Phase:
Phase 1
Details
Lead Sponsor:
Bayer
Treatments:
Albumin-Bound Paclitaxel
Bevacizumab
Carboplatin
Niacinamide
Paclitaxel
Sorafenib